These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
180 related articles for article (PubMed ID: 32908253)
1. Pseudosarcomatous myofibroblastic proliferations of the urinary bladder are neoplasms characterized by recurrent FN1-ALK fusions. Acosta AM; Demicco EG; Dal Cin P; Hirsch MS; Fletcher CDM; Jo VY Mod Pathol; 2021 Feb; 34(2):469-477. PubMed ID: 32908253 [TBL] [Abstract][Full Text] [Related]
2. Pseudosarcomatous myofibroblastic proliferations of the genitourinary tract are genetically different from nodular fasciitis and lack USP6, ROS1 and ETV6 gene rearrangements. Jebastin JAS; Smith SC; Perry KD; Gupta NS; Alanee S; Carskadon S; Chitale DA; Palanisamy N; Williamson SR Histopathology; 2018 Aug; 73(2):321-326. PubMed ID: 29617048 [TBL] [Abstract][Full Text] [Related]
4. Uterine inflammatory myofibroblastic tumor: First report of a ROS1 fusion. Bennett JA; Wang P; Wanjari P; Diaz L; Oliva E Genes Chromosomes Cancer; 2021 Dec; 60(12):822-826. PubMed ID: 34322931 [TBL] [Abstract][Full Text] [Related]
5. Inflammatory myofibroblastic tumor of the urinary bladder with FN1‑ALK gene fusion: A case report. Son SM; Woo CG; Lee OJ; Kim YJ; Lee HC Oncol Lett; 2023 Jun; 25(6):227. PubMed ID: 37153035 [TBL] [Abstract][Full Text] [Related]
6. TERT promoter mutation analysis as a surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder. Bertz S; Stöhr R; Gaisa NT; Wullich B; Hartmann A; Agaimy A Histopathology; 2020 Dec; 77(6):949-962. PubMed ID: 32645760 [TBL] [Abstract][Full Text] [Related]
7. Inflammatory Myofibroblastic Tumor of the Bladder With FN1-ALK Gene Fusion: Different Response to ALK Inhibition. Reinhart S; Trachsel Y; Fritz C; Wagner U; Bode-Lesniewska B; John H; Pless M Urology; 2020 Dec; 146():32-35. PubMed ID: 33007314 [TBL] [Abstract][Full Text] [Related]
8. Expression of ROS1 predicts ROS1 gene rearrangement in inflammatory myofibroblastic tumors. Hornick JL; Sholl LM; Dal Cin P; Childress MA; Lovly CM Mod Pathol; 2015 May; 28(5):732-9. PubMed ID: 25612511 [TBL] [Abstract][Full Text] [Related]
9. Pregnancy-associated Inflammatory Myofibroblastic Tumors of the Uterus Are Clinically Distinct and Highly Enriched for TIMP3-ALK and THBS1-ALK Fusions. Devereaux KA; Fitzpatrick MB; Hartinger S; Jones C; Kunder CA; Longacre TA Am J Surg Pathol; 2020 Jul; 44(7):970-981. PubMed ID: 32271187 [TBL] [Abstract][Full Text] [Related]
10. Utility of ALK-1 protein expression and ALK rearrangements in distinguishing inflammatory myofibroblastic tumor from malignant spindle cell lesions of the urinary bladder. Sukov WR; Cheville JC; Carlson AW; Shearer BM; Piatigorsky EJ; Grogg KL; Sebo TJ; Sinnwell JP; Ketterling RP Mod Pathol; 2007 May; 20(5):592-603. PubMed ID: 17396140 [TBL] [Abstract][Full Text] [Related]
11. FN1: a novel fusion partner of ALK in an inflammatory myofibroblastic tumor. Ouchi K; Miyachi M; Tsuma Y; Tsuchiya K; Iehara T; Konishi E; Yanagisawa A; Hosoi H Pediatr Blood Cancer; 2015 May; 62(5):909-11. PubMed ID: 25682942 [TBL] [Abstract][Full Text] [Related]
12. Inflammatory myofibroblastic tumour of the urinary bladder: the role of immunoglobulin G4 and the comparison of two immunohistochemical antibodies and fluorescence in-situ hybridization for the detection of anaplastic lymphoma kinase alterations. Choi E; Williamson SR; Montironi R; Zhang S; Wang M; Eble JN; Grignon DJ; Lopez-Beltran A; Idrees MT; Baldridge LA; Scarpelli M; Jones CL; Wang L; MacLennan GT; Osunkoya AO; Cheng L Histopathology; 2015 Jul; 67(1):20-38. PubMed ID: 25406945 [TBL] [Abstract][Full Text] [Related]
14. ALK expression in pseudosarcomatous myofibroblastic proliferations of the genitourinary tract. Hirsch MS; Dal Cin P; Fletcher CD Histopathology; 2006 Apr; 48(5):569-78. PubMed ID: 16623783 [TBL] [Abstract][Full Text] [Related]
15. Anaplastic lymphoma kinase-negative uterine inflammatory myofibroblastic tumor containing the ETV6-NTRK3 fusion gene: a case report. Takahashi A; Kurosawa M; Uemura M; Kitazawa J; Hayashi Y J Int Med Res; 2018 Aug; 46(8):3498-3503. PubMed ID: 29900760 [TBL] [Abstract][Full Text] [Related]
16. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma. Hung YP; Dong F; Watkins JC; Nardi V; Bueno R; Dal Cin P; Godleski JJ; Crum CP; Chirieac LR JAMA Oncol; 2018 Feb; 4(2):235-238. PubMed ID: 28910456 [TBL] [Abstract][Full Text] [Related]
17. ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor. Debiec-Rychter M; Marynen P; Hagemeijer A; Pauwels P Genes Chromosomes Cancer; 2003 Oct; 38(2):187-90. PubMed ID: 12939746 [TBL] [Abstract][Full Text] [Related]
18. Infantile inflammatory myofibroblastic tumors: clinicopathological and molecular characterization of 12 cases. Lopez-Nunez O; John I; Panasiti RN; Ranganathan S; Santoro L; Grélaud D; Wu T; Buccoliero AM; Casanova M; Alaggio R; Surrey LF Mod Pathol; 2020 Apr; 33(4):576-590. PubMed ID: 31690781 [TBL] [Abstract][Full Text] [Related]
19. [Clinicopathologic features and immunophenotype of pseudosarcomatous myofibroblastic proliferation of urinary bladder]. Zhang YH; Zhang XR; Yu J; Li HL Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):585-590. PubMed ID: 30107662 [No Abstract] [Full Text] [Related]
20. Clinicopathologic and Genomic Characterization of Inflammatory Myofibroblastic Tumors of the Head and Neck: Highlighting a Novel Fusion and Potential Diagnostic Pitfall. Kerr DA; Thompson LDR; Tafe LJ; Jo VY; Neyaz A; Divakar P; Paydarfar JA; Pastel DA; Shirai K; John I; Seethala RR; Salgado CM; Deshpande V; Bridge JA; Kashofer K; Brčić I; Linos K Am J Surg Pathol; 2021 Dec; 45(12):1707-1719. PubMed ID: 34001695 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]